Avantax Advisory Services, Inc. Avadel Pharmaceuticals PLC Transaction History

Avantax Advisory Services, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$12.55 - $17.22 $387,242 - $531,340	30,856 Added 123.92%	55,756 $941,000
Q4 2023 Feb 07, 2024	BUY	$9.64 - $14.59 $8,676 - $13,131	900 Added 3.75%	24,900 $351,000
Q2 2023 Aug 11, 2023	BUY	$8.48 - $16.48 $21,200 - $41,200	2,500 Added 11.63%	24,000 $395,000
Q1 2023 Apr 28, 2023	BUY	$6.41 - $9.95 $57,690 - $89,550	9,000 Added 72.0%	21,500 $196,000
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $5,020 - $10,000	-1,000 Reduced 7.41%	12,500 $89,000
Q2 2022 Aug 02, 2022	SELL	$1.07 - $6.95 $535 - $3,475	-500 Reduced 3.57%	13,500 $33,000
Q1 2022 Apr 27, 2022	SELL	$5.46 - $8.29 $60,060 - $91,189	-11,000 Reduced 44.0%	14,000 $96,000
Q3 2021 Oct 21, 2021	BUY	$6.49 - $9.91 $12,980 - $19,820	2,000 Added 8.7%	25,000 $248,000
Q2 2021 Jul 29, 2021	BUY	$6.73 - $9.05 $23,555 - $31,675	3,500 Added 17.95%	23,000 $154,000
Q1 2021 May 13, 2021	BUY	$6.61 - $10.07 $128,895 - $196,365	19,500 New	19,500 $177,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Advisory Services, Inc. with notifications on news.